Holen Sie sich die Stockscreener-App
90.20
2.13%
-1.96
Handel nachbörslich:
92.90
2.70
+2.99%
Schlusskurs vom Vortag:
$92.16
Offen:
$91.7
24-Stunden-Volumen:
742.94K
Relative Volume:
0.43
Marktkapitalisierung:
$5.44B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-116.25M
KGV:
-37.72
EPS:
-2.3912
Netto-Cashflow:
$-91.19M
1W Leistung:
-1.65%
1M Leistung:
-0.44%
6M Leistung:
+158.45%
1J Leistung:
+532.98%
1-Tages-Spanne:
$89.37
$93.50
1-Wochen-Bereich:
$89.37
$96.00
52-Wochen-Spanne:
$12.84
$97.78
Oruka Therapeutics Inc Stock (ORKA) Company Profile
Firmenname
Oruka Therapeutics Inc
Sektor
Branche
Telefon
650-606-7910
Adresse
855 OAK GROVE AVE., MENLO PARK
Compare ORKA vs VRTX, REGN, ARGX, RVMD, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
90.20 | 5.56B | 0 | -116.25M | -91.19M | -2.3912 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-18 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-13 | Eingeleitet | Jefferies | Buy |
| 2025-10-27 | Eingeleitet | Guggenheim | Buy |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-05-22 | Eingeleitet | BTIG Research | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-11 | Eingeleitet | Stifel | Buy |
| 2024-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | Leerink Partners | Outperform |
| 2024-09-16 | Eingeleitet | TD Cowen | Buy |
| 2024-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-02-27 | Eingeleitet | Ascendiant Capital Markets | Buy |
| 2013-10-09 | Eingeleitet | Dawson James | Buy |
Alle ansehen
Oruka Therapeutics Inc Aktie (ORKA) Neueste Nachrichten
Oruka Therapeutics Inc (ORKA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oruka Therapeutics Inc (ORKA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oruka Therapeutics Inc (ORKA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
ORKA|Oruka Therapeutics Inc|Price:92.160|Chg%:+0.210 - TradingKey
Oruka Therapeutics, Inc. Revenue Breakdown – NASDAQ:ORKA - TradingView
ORKA Stock Is Soaring After Psoriasis Trial Results — Here's Why BTIG Hiked Its Price Target By 94% - Stocktwits
Oruka Therapeutics Inc (ORKA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oruka Therapeutics Inc. (ORKA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
ORKA Stock Climbs As Traders Track Tight Range - StocksToTrade
ORKA Stock Grinds Higher As Traders Track Tight Range - timothysykes.com
ORKA Stock Climbs As Traders Track Strong Cash Runway - StocksToTrade
Oruka Therapeutics Rises as Investors Focus on Pipeline Data Setup - Quiver Quantitative
Form 144 ORUKA THERAPEUTICS INC For: 15 July By Investing.com - Investing.com Australia
Oruka Therapeutics CMO Joana Goncalves sells $603,937 in shares - Investing.com UK
Form 4 Oruka Therapeutics Inc For: 15 July By Investing.com - Investing.com Nigeria
Oruka Therapeutics CMO Joana Goncalves sells $603,937 in shares By Investing.com - Investing.com Nigeria
Form 4 Oruka Therapeutics Inc For: 15 July - Investing.com UK
Form 144 ORUKA THERAPEUTICS INC For: 15 July - Investing.com UK
BTIG Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $151 - Moomoo
Form 4 Oruka Therapeutics Inc For: 13 July By Investing.com - Investing.com South Africa
Oruka Therapeutics SVP sells $846k in stock By Investing.com - Investing.com Nigeria
Form 144 Oruka Therapeutics For: 13 July By Investing.com - Investing.com Australia
Oruka Therapeutics Insider Sold Shares Worth $846,180, According to a Recent SEC Filing - Moomoo
Oruka Therapeutics SVP sells $846k in stock - Investing.com
Form 144 Oruka Therapeutics For: 13 July - Investing.com UK
Oruka TherapeuticsIntriguing Long Acting Psoriasis Programs May Need Further Derisking - Seeking Alpha
How Investors May Respond To Oruka Therapeutics (ORKA) Russell Index Shift Toward Small-Cap Growth Benchmarks - simplywall.st
Oruka Therapeutics Shares Drop After Hours After Fairmount Unloads 3.55 Million Shares - MSN
Oruka Therapeutics (ORKA) Holds Steady Near Resistance Amid Low VolatilityOption Breadth - dars.gov.et
Oruka Therapeutics (ORKA) Recast By Russell Growth Shift On A Valuation That Looks About Right - Sahm
Why Oruka Therapeutics (ORKA) Is Up 13.6% After Russell Index Reclassification Into Growth Benchmarks - Sahm
UBS Maintains Oruka Therapeutics(ORKA.US) With Buy Rating, Maintains Target Price $130 - Moomoo
Oruka Therapeutics (ORKA) Sees 8.1% Decline - GuruFocus
Oruka Therapeutics Insider Sold Shares Worth $472,079, According to a Recent SEC Filing - marketscreener.com
Fairmount Healthcare Fund II sells $300m Oruka Therapeutics stock By Investing.com - Investing.com India
Form 144 | Oruka Therapeutics(ORKA.US) Insider Proposes to Sell 300.01 Million in Common Stocks - Moomoo
Insider Sell: Laura Sandler Sells 5,000 Shares of Oruka Therapeu - GuruFocus
Form 144 Oruka Therapeutics For: 1 July By Investing.com - Investing.com Nigeria
Form 13D/A ORUKA THERAPEUTICS For: 1 July By Investing.com - Investing.com Nigeria
Fairmount Healthcare Fund II sells $300m Oruka Therapeutics stock - Investing.com
Form 144 Oruka Therapeutics For: 1 July - Investing.com UK
Finanzdaten der Oruka Therapeutics Inc-Aktie (ORKA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):